Further screens have identified small molecule inhibitors of protein–protein interactions of Myc-Max, such as Mycro3 and KJ-Pyr-9, which had improved pharmacokinetics, bioavailability and overall in vivo activity and demonstrated efficacy in mouse models of pancreatic and breast cancers. This evidence concerns the gene MYC and breast carcinoma.